Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2):150-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  BONE METASTASES IN THE ERA OF TARGETED TREATMENTS 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2):150-8

DOI: 10.23736/S1824-4785.19.03193-5

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Response assessment of bone metastatic disease: seeing the forest for the trees
 RECIST, PERCIST, iRECIST, and PCWG-2

Angelo CASTELLO, Egesta LOPCI

Nuclear Medicine Unit, Humanitas Clinical and Research Hospital, IRCCS, Rozzano, Milan, Italy



Tumor response is often used as a surrogate marker for survival practically in all clinical trials. Therefore, robust and valid response criteria during the course of trials are fundamental for the assessment of response to therapy. This aspect, however, becomes particularly challenging when it comes to bone metastases. In the era of targeted therapies and immune-checkpoint inhibitors (ICI), response assessment by morphologic-based criteria cannot detect the real tumor response and, consequently, fail to demonstrate the actual clinical benefit. This review will focus on some of the most common morphologic and metabolic response criteria and their application for bone lesions, highlighting relative strengths and weaknesses as well as potential future methods in the era of target therapies and immunotherapy with ICI.


KEY WORDS: Bone neoplasms; Neoplasm metastases; Clinical trials as topic; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Treatment outcome

top of page